LIPPS RANDALL A 4
4 · OMNICELL, INC. · Filed Dec 3, 2025
Insider Transaction Report
Form 4
OMNICELL, INC.OMCL
LIPPS RANDALL A
DirectorCHAIRMAN, PRESIDENT AND CEO
Transactions
- Exercise/Conversion
Common Stock
2025-12-01$27.70/sh+28,250$782,525→ 414,898 total - Sale
Common Stock
2025-12-01$35.97/sh−28,250$1,016,093→ 386,648 total - Exercise/Conversion
Stock Option NQ (Right to Buy)
2025-12-01−28,250→ 0 totalExercise: $27.70Exp: 2026-02-04→ Common Stock (28,250 underlying)
Holdings
- 355,861(indirect: By Trust)
Common Stock
- 8,051(indirect: By Trust)
Common Stock
Footnotes (5)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.
- [F2]The price reported in Column 4 is a weighted average price of $35.9679. The sold price range between $35.65 to $36.4746. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Shares held in trust with Mr. Lipps' wife.
- [F4]Shares held in trust for the benefit of Mr. Lipps' children.
- [F5]The options were granted on 2/4/2016 with 25% vested on the one-year anniversary of the grant date and the reaming amount vesting ratably over a 36 month period. The options were fully vested on 2/4/2020.